NewAmsterdam Pharma Company (NAMS) Price & Analysis

Compare

238 Followers

NAMS Stock Chart & Stats

$36.40

-$0.03(-0.12%)

At close: Jan 08 4:00 PM EST

$36.40

-$0.03(-0.12%)

Day’s Range― - ―

52-Week Range$14.06 - $41.47

Previous CloseN/A

Volume118.30K

Average Volume (3M)1.27M

Market Cap

$4.11B

Enterprise Value$1.41B

Total Cash (Recent Filing)$739.16M

Total Debt (Recent Filing)$328.00K

Price to Earnings (P/E)―

Beta1.81

Next Earnings

Nov 17, 2025

EPS Estimate

-0.41

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding112,628,456

10 Day Avg. Volume1,692,559

30 Day Avg. Volume1,270,765

Financial Highlights & Ratios

PEG Ratio-0.53

Price to Book (P/B)3.20

Price to Sales (P/S)53.22

P/FCF Ratio-15.23

Enterprise Value/Market Cap0.34

Enterprise Value/Revenue22.00

Enterprise Value/Gross Profit22.00

Enterprise Value/Ebitda-5.87

Forecast

1Y Price Target

$42.11

Price Target Upside15.69% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

Alzheimer's Disease ResearchPositive results in the Alzheimer’s sub-study were observed across the intent-to-treat population as well as the ApoE4 carriers.

Financial StabilityThe company maintained a solid cash position of ~$783M, which will amply support operations through key value-creating milestones.

Product DifferentiationObicetrapib is believed to offer a differentiated product profile in the marketplace.

Bears Say

Investor ConcernsThe lack of numerical data in Merck’s press release could lead some investors to assume the results are not as strong as the previous Phase II trials.

NewAmsterdam Pharma Company News

NewAmsterdam Pharma price target raised to $50 from $42 at Citi

Citi raised the firm’s price target on NewAmsterdam Pharma (NAMS) to $50 from $42 and keeps a Buy...

2d ago

NAMS

NewAmsterdam Pharma Highlights Progress in Obicetrapib Trials

NewAmsterdam Pharma Company ( ($NAMS) ) just unveiled an update. On September 2, 2025, NewAmsterdam Pharma Company released...

2M ago

NAMS

NewAmsterdam Pharma initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of NewAmsterdam Pharma (NAMS) with an Overweight rating and $45 price target The firm...

2M ago

NAMS

NewAmsterdam Pharma’s EMA Validation for Obicetrapib

The latest announcement is out from NewAmsterdam Pharma Company ( ($NAMS) ). On August 18, 2025, NewAmsterdam Pharma...

2M ago

NAMS

NewAmsterdam announces acceptance of MAA for review by EMA for obicetrapib

NewAmsterdam Pharma (NAMS) Company N.V. announced that the European Medicines Agency, EMA, has validated the Marketing Authorization Application,...

2M ago

NAMS

NewAmsterdam Pharma Signs Supply Agreement with Menarini

NewAmsterdam Pharma Company ( ($NAMS) ) has shared an update. On August 12, 2025, NewAmsterdam Pharma’s subsidiary entered...

2M ago

NAMS

Promising Future for NewAmsterdam Pharma: Buy Rating Backed by Strong Financials and Positive Trial Data

Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on NAMS stock, giving a Buy rating yesterday....

2M ago

NAMS

NewAmsterdam Pharma Reports Q2 2025 Financial Results

Newamsterdam Pharma Company N.V. ( ($NAMS) ) has released its Q2 earnings. Here is a breakdown of the...

2M ago

NAMS

Promising Developments and Strong Financial Position Support Buy Rating for NewAmsterdam Pharma

In a report released today, Serge Belanger from Needham maintained a Buy rating on NewAmsterdam Pharma Company, with...

2M ago

NAMS

Buy Rating for NewAmsterdam Pharma Driven by Promising Trial Developments and Strategic Advancements

William Blair analyst Matt Phipps has maintained their bullish stance on NAMS stock, giving a Buy rating today....

2M ago

NAMS

Optimistic Buy Rating for NewAmsterdam Pharma Driven by Promising Cardiometabolic Drug Developments

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on NAMS stock, giving a Buy rating...

2M ago

NAMS

NewAmsterdam Pharma reports Q2 revenue $19.145M vs $2.279M last year

“Fueled by strong momentum in the first half of 2025, obicetrapib is rapidly advancing towards patients worldwide, potentially...

2M ago

NAMS

Buy Rating for NewAmsterdam Pharma: Promising Developments in Alzheimer’s and Cardiovascular Trials

Leerink Partners analyst Roanna Ruiz maintained a Buy rating on NewAmsterdam Pharma Company on July 30 and set...

3M ago

NAMS

Promising Alzheimer’s Biomarker Data and Expert Enthusiasm Drive Buy Rating for NewAmsterdam Pharma

NewAmsterdam Pharma Company, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger...

3M ago

NAMS

NAMS FAQ

What was NewAmsterdam Pharma Company’s price range in the past 12 months?

NewAmsterdam Pharma Company lowest stock price was $14.06 and its highest was $41.47 in the past 12 months.

What is NewAmsterdam Pharma Company’s market cap?

NewAmsterdam Pharma Company’s market cap is $4.11B.

When is NewAmsterdam Pharma Company’s upcoming earnings report date?

NewAmsterdam Pharma Company’s upcoming earnings report date is Nov 17, 2025 which is in 29 days.

How were NewAmsterdam Pharma Company’s earnings last quarter?

NewAmsterdam Pharma Company released its earnings results on Aug 06, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.463 by $0.313.

Is NewAmsterdam Pharma Company overvalued?

According to Wall Street analysts NewAmsterdam Pharma Company’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does NewAmsterdam Pharma Company pay dividends?

NewAmsterdam Pharma Company does not currently pay dividends.

What is NewAmsterdam Pharma Company’s EPS estimate?

NewAmsterdam Pharma Company’s EPS estimate is -0.41.

How many shares outstanding does NewAmsterdam Pharma Company have?

NewAmsterdam Pharma Company has 112,628,456 shares outstanding.

What happened to NewAmsterdam Pharma Company’s price movement after its last earnings report?

NewAmsterdam Pharma Company reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.463. Following the earnings report the stock price went up 8.698%.

Which hedge fund is a major shareholder of NewAmsterdam Pharma Company?

Currently, no hedge funds are holding shares in NAMS

NewAmsterdam Pharma Company Stock Smart Score

Outperform

Fundamentals

Return on Equity

-28.43%

Trailing 12-Months

Asset Growth

82.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

NewAmsterdam Pharma Company

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

NewAmsterdam Pharma Company (NAMS) Earnings & Revenues

Historic Earnings Reports

NAMS Stock 12 Month Forecast

Average Price Target

$42.11

▲(15.69% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","53":"$53","25.25":"$25.3","34.5":"$34.5","43.75":"$43.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$42.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,25.25,34.5,43.75,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.36,31.10153846153846,32.84307692307692,34.58461538461538,36.326153846153844,38.067692307692305,39.809230769230766,41.550769230769234,43.29230769230769,45.033846153846156,46.77538461538461,48.51692307692308,50.25846153846154,{"y":52,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.36,30.34076923076923,31.32153846153846,32.30230769230769,33.28307692307692,34.26384615384615,35.244615384615386,36.22538461538461,37.206153846153846,38.18692307692308,39.167692307692306,40.14846153846154,41.129230769230766,{"y":42.11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.36,29.409230769230767,29.45846153846154,29.507692307692306,29.556923076923077,29.606153846153845,29.655384615384616,29.704615384615384,29.753846153846155,29.803076923076922,29.852307692307694,29.90153846153846,29.950769230769232,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.29,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.82,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.29,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.63,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >